RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2021)
RedHill Biopharma's (RDHL) quarterly Non-Current Debt came in at $83.6 million in Q4 2021, up 2.74% year-over-year from $81.4 million in Q4 2020, and up 0.55% quarter-over-quarter from $83.2 million in Q2 2021.
Powered by 
Analysis
RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2021) Analysis & Trends
RedHill Biopharma (RDHL) has reported Non-Current Debt for 2 consecutive years, with $83.6 million the latest figure, recorded in Q4 2021.
- On a quarterly basis, Non-Current Debt rose 2.74% year-over-year to $83.6 million in Q4 2021; TTM through Dec 2021 was $83.6 million, a 2.74% increase from a year earlier, with the FY2021 full-year figure at $83.6 million, up 2.74% from the prior year.
- Non-Current Debt was $83.6 million for Q4 2021 at RedHill Biopharma, up from $83.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $83.6 million in Q4 2021 and troughed at $79.2 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 12.09 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 11.61 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 150.67 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 2.57 Bn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 20.74 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 280.16 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 1.26 Bn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 609.56 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 10.63 Mn | 10.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 83.62 Mn |
| Jun 30, 2021 | 83.16 Mn |
| Dec 31, 2020 | 81.39 Mn |
| Jun 30, 2020 | 79.19 Mn |